Latest Ratios: P/E Ratio -7.4x · EV/EBITDA N/A · ROE -28.2%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.2B | $368M | — | — |
| Enterprise Value | $1.1B | $1.1B | $313M | — | — |
| P/E Ratio → | -7.43 | — | — | — | — |
| P/S Ratio | 55.96 | — | — | — | — |
| P/B Ratio | 1.88 | 2.44 | 1.20 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -28.2% | -28.2% | -56.0% | — | -54.6% |
| ROA | -26.9% | -26.9% | -33.3% | -37.2% | -33.7% |
| ROIC | -27.1% | -27.1% | -79.6% | — | — |
| ROCE | -31.3% | -31.3% | -36.7% | -41.0% | -34.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | — | 0.53 |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.18 | — | -1.06 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -36.38 |
Net cash position: cash ($53M) exceeds total debt ($11M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 26.17 | 26.17 | 35.34 | 17.14 | 18.80 |
| Quick Ratio | 26.17 | 26.17 | 35.34 | 17.14 | 18.80 |
| Cash Ratio | 25.75 | 25.75 | 34.82 | 16.75 | 18.74 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $39M | $21M | $2M | $20M |
Includes 30+ ratios · 4 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RAPP stock.
Rapport Therapeutics, Inc. Common Stock's current P/E ratio is -7.4x. This places it at the 50th percentile of its historical range.
Rapport Therapeutics, Inc. Common Stock's return on equity (ROE) is -28.2%. The historical average is -46.3%.
Based on historical data, Rapport Therapeutics, Inc. Common Stock is trading at a P/E of -7.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Equity dilution funding dependence
Metrics are mathematically derived from official filings.
Premium Valuation Without Earnings Support
Based on reported figures, RAPP trades at 58.44 times sales and 1.96 times book value while earning negative returns, so the market is pricing pipeline optionality rather than current earnings power or revenue scale. This gap between price and fundamentals is typical of pre-revenue biotech and leaves the stock sensitive to trial readouts.
A price-to-sales multiple above 58 is only meaningful for a company with a commercial revenue base, and RAPP has none, so the metric mainly reflects the market's assessment of the RAP-219 program. The 1.96 price-to-book ratio is more informative here, suggesting the market values the platform at roughly twice the stated equity base of $391.2M. Investors should monitor whether pivotal data can justify that premium before dilution erodes per-share value.
Minimal Debt Masks Equity Erosion
As reported in the balance sheet, RAPP's debt-to-equity ratio of 0.02 looks conservative, yet equity has fallen to $391.2M as the accumulated deficit reached -$351.9M, indicating the capital base is shrinking through losses.
A near-zero leverage ratio reflects the absence of debt rather than balance sheet strength, since the company has no earnings to cover interest and no debt service capacity is being tested. The more relevant pressure is the steady erosion of equity, which suggests future capital needs will likely be met through issuance. Interest coverage is not meaningful given the lack of operating income.
Cash Cover Measured in Quarters
According to reported financials, RAPP's current ratio of 20.07 reflects a large current asset base against minimal liabilities, but $74.8M in cash against a $41.6M quarterly operating outflow implies only about two quarters of coverage at current burn.
The very high current ratio is a function of a small liability base rather than abundant excess liquidity, so it overstates the cushion available to fund trials. Stress testing liquidity against the most recent burn rate indicates the position could tighten quickly as pivotal activity ramps. The quick ratio tracks the current ratio exactly, consistent with negligible inventory, so liquidity depends entirely on cash and equity access.
Negative Returns Driven by Clinical Burn
Based on reported figures, RAPP's ROE of -9.9% and ROIC of -9.5% in 2026Q3 are negative and have deteriorated from the -4.2% ROE recorded in 2026Q1, reflecting losses that are growing faster than the capital base.
Negative ROIC is expected for a clinical-stage company, but the trend matters: returns have moved deeper into negative territory as R&D spend ramped toward roughly $51M per quarter. Because the denominator is a shrinking equity base, ROE can look less severe than the underlying loss trajectory suggests. These ratios should be read as a measure of capital consumption rather than a failure of capital efficiency at this stage.
Lagging Peers on Returns, Leading on Balance Sheet
Compared with peers such as ACADIA at 28.0% ROE and INVA at 15.8% ROE, RAPP's negative returns and 0.02 debt-to-equity place it at the opposite end of the profitability spectrum, though its leverage is among the lowest in the group.
The return gap is structural to RAPP's pre-revenue stage rather than a temporary execution problem, since peers generate earnings from commercial operations. Its low leverage is a genuine strength relative to the group, but it reflects the absence of debt financing rather than a deliberate capital structure advantage. The relevant comparison for RAPP is with other clinical-stage CNS developers, where it should be judged on pipeline progress and cash runway.
Misapplied Gross Margin Metric
The ratio most commonly misapplied to RAPP is the price-to-sales multiple, which appears inflated at 58.44 times on negligible revenue and obscures the cash burn that actually drives valuation risk.
Applying sales-based multiples to a company whose revenue is a single non-recurring quarter of $20.0M produces a figure that reflects the market's optionality on RAP-219 rather than any revenue base. A more appropriate lens is cash runway per share and the probability-weighted value of pivotal readouts, since these capture the equity dilution path. Investors should monitor quarterly operating outflows against the $74.8M cash balance to assess how much time remains before financing is required.